Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis

Thoracic Cancer
Maako IdeIsamu Okamoto

Abstract

The efficacy and safety of immune-checkpoint inhibitors in non-small cell lung cancer patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Herein, we describe the case of a 62-year-old man with multiple pleural tumors and carcinomatous pleurisy. High-resolution computed tomography indicated usual interstitial pneumonia, and a respiratory function test revealed a restrictive disorder and decreased diffusion capacity. He was diagnosed with lung adenocarcinoma and IPF. After failure of initial chemotherapy, he was treated with nivolumab and achieved a complete response without any sign of exacerbation of IPF. The response to nivolumab has persisted for > 1 year. This is the first report of a non-small cell lung cancer patient with IPF who has been treated with immune-checkpoint inhibitors for such a long period and achieved a sustained response.

References

Aug 10, 2002·Journal of Cellular and Molecular Medicine·K DemopoulosD A Spandidos
Apr 8, 2011·American Journal of Respiratory and Critical Care Medicine·Ganesh RaghuUNKNOWN ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jun 21, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Monica Khunger, Vamsidhar Velcheti
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Aug 26, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Daichi FujimotoKeisuke Tomii

❮ Previous
Next ❯

Citations

Oct 11, 2019·European Respiratory Review : an Official Journal of the European Respiratory Society·Jacques CadranelVincent Fallet
Jul 15, 2020·Journal of Clinical Pharmacy and Therapeutics·Jing HuXiangrong Zuo
Nov 7, 2019·Respirology : Official Journal of the Asian Pacific Society of Respirology·Haruki KobayashiToshiaki Takahashi
Sep 29, 2019·Journal of Clinical Medicine·JanWillem DuitmanC Arnold Spek
Feb 2, 2019·International Journal of Molecular Sciences·Beatriz BallesterJulio Cortijo

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.